Gins1-flox Mouse

GINS1, a subunit of the GINS complex, functions in eukaryotic DNA replication, collaborating with the MCM2-7 complex and Cdc45. It plays a significant role in cell cycle modulation, which is crucial for DNA replication and cell proliferation [3,4].

GINS1 is overexpressed in multiple cancers such as leukemia, DLBCL, hepatocellular carcinoma, glioma, bladder cancer, gastric cancer, sarcoma, and lung adenocarcinoma, and is associated with poor prognosis in these malignancies. In DLBCL, the FOXP1-GINS1 axis promotes cell proliferation and doxorubicin resistance [1]. In hepatocellular carcinoma, GINS1 promotes ZEB1-mediated epithelial-mesenchymal transition and tumor metastasis via β-catenin signaling [2]. In glioma, GINS1 promotes cell proliferation and migration through USP15-mediated deubiquitination of TOP2A [3]. In bladder cancer, GINS1 promotes the initiation and progression by activating the AKT/mTOR/c-Myc signaling pathway [4]. In sarcoma, it is overexpressed in metastatic samples, and its alteration is linked to worse survival [5]. In lung adenocarcinoma, GINS1 facilitates development via Wnt/β-catenin activation [6].

In conclusion, GINS1 is essential in DNA replication and cell cycle-related processes. Its overexpression in various cancers reveals its significant role in cancer development and progression, making it a potential therapeutic target. Mouse models, if studied, could further elucidate its role in these disease conditions, providing more insights into its functions and potential treatments.